Loading…
FENC
Fennec Pharmaceuticals Inc
NASDAQ· Healthcare· Biotechnology
$12.27+4.25%
Key metrics
- Market cap
- $430.27M
- P/E
- —
- Forward P/E
- 12.9x
- P/B
- 10.1x
- Dividend yield
- —
- EPS
- -$0.12
- ROE
- -18.58%
- Profit margin
- -5.49%
- Revenue growth
- +85.20%
- Beta
- 1.07
- 52-week high
- $13.25
- 52-week low
- $5.65
History
How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
About the company
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
- 35
- Research Triangle Park, United States
Company description provided by Yahoo Finance.